Americann Inc. (ACAN: OTCQX U.S.) | AmeriCann (ACAN) to Present at the 9th Annual LD Micro Main Event


AmeriCann (ACAN) to Present at the 9th Annual LD Micro Main Event

Nov 22, 2016

OTC Disclosure News Service

Denver, CO

Inc. (OTCQX: ACAN), a company that is developing sustainable, state-of-the-art
medical cannabis cultivation properties, announced today that it will be presenting at the 9th annual LD Micro Main Event
on Wednesday, December 7 at 5:00 PM PST. 
The LD Micro Main Event is the largest independent conference for
small/microcap companies and will be held
6-8, 2016 at the Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los
Angeles, California


AmeriCann’s President and CEO,
Tim Keogh, will be presenting, as well as meeting one-on-one with investors
throughout the event discussing the company and the Massachusetts Medical
Cannabis Center.


The regulated cannabis
industry is expected is to be one of the fastest growing industries in the
country.  The respected Wall Street firm
of Cowen Co recently released a research report projecting dramatic growth
for the industry from the current $7 billion nationally to over $50 billion in
ten years.

Massachusetts, California,
Maine, and Nevada voted to legalize recreational marijuana while Arkansas and
North Dakota approved medical cannabis initiatives.  Florida voters
approved medical marijuana in a landslide with over 71% of the vote.  With
these election results, over 60% of the US Population now live in states where
medical cannabis is now legal.

Micro Main Event

Location: Luxe Sunset Bel Air

Date: Wednesday, December 7

Time: 5:00 PM PST / 8:00 PM EST

The LD Micro Main
Event is the largest independent conference for small / microcap companies and
will feature 240 presenting corporations.


AmeriCann is a publicly traded
company that plans to develop and lease sustainable, state-of-the-art medical
cannabis cultivation properties. The Company has over 1,000,000 square feet of
facilities in the planning and design stages of development.  The Company has designed a proprietary line
of cannabis infused products which will be branded and licensed to companies in
regulated markets.

AmeriCann, Inc. is a Certified B Corp, an acknowledgment of the
company’s commitment to social and environmental ethics, transparency and
AmeriCann became the first public
cannabis company

to earn this respected accreditation. More information about the Company is
available at:

About Massachusetts
Medical Cannabis Center

The Massachusetts Medical
Cannabis Center is approved for nearly 
1,000,000 square
medical cannabis cultivation and processing in Freetown, Massachusetts. The
state-of-the-art, sustainable, greenhouse project will consist of multiple
planned phases for tenants in the Massachusetts medical marijuana market.  AmeriCann’s Cannopy System uniquely combines
expertise from traditional horticulture, lean manufacturing, regulatory
compliance and cannabis cultivation to create superior facilities and

The first phase of the project
consists of 130,000 sq. ft. of cultivation and processing infrastructure.
AmeriCann can expand the first phase to approximately 600,000 sq. ft., based on
patient demand.

About LD Micro

LD Micro was
founded in 2006 with the sole purpose of being an independent resource in the
microcap space. What started out as a newsletter highlighting unique companies
has transformed into an event platform hosting several influential conferences
annually (Invitational, Summit, and Main Event).

In 2015, LDM
launched the first pure microcap index (the LDMi) to exclusively provide
intraday information on the entire sector. LD will continue to provide valuable
tools for the benefit of everyone in the small and microcap universe.

For those
interested in attending, please contact David Scher at or visit for more



This press release contains
“forward-looking statements” within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as
part of the Private Securities Litigation Reform Act of 1995). Statements
preceded by, followed by or that otherwise include the words “believe,”
“anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,”
“outlook,” and similar words or expressions, or future or conditional verbs
such as “will,” “should,” “would,” “may,” and “could” are generally
forward-looking in nature and not historical facts. These forward-looking
statements involve known and unknown risks, uncertainties and other factors
which may cause the Company’s actual results, performance or achievements to be
materially different from any anticipated results, performance or achievements.
The Company disclaims any intention to, and undertakes no obligation to, revise
any forward-looking statements, whether as a result of new information, a
future event, or otherwise. For additional uncertainties that could impact the
Company’s forward-looking statements, please see the Company’s Annual Report on
Form 10-K for the year ended September 30, 2015, which the Company has filed
with the SEC and which may be viewed at

Contact Information:


AmeriCann, Inc.

3200 Brighton Blvd. Unit 114

Denver, CO 80216









/* Style Definitions */
{mso-style-name:”Table Normal”;
mso-padding-alt:0in 5.4pt 0in 5.4pt;

Copyright © 2016 OTC Markets. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Leave a Reply